Memphasys (ASX: MEM) is commercialising the Felix™ System globally. CE Mark certified. TGA registered. UK MHRA registered. Revenue-generating with repeat cartridge orders across Europe, the Middle East and Japan. The Company delivered record quarterly revenue of A$111.6k in the March 2026 quarter - a step-change from A$8.8k in the December 2025 quarter - confirming the transition to a recurring revenue model. Multi-year commercial agreements are active across Europe, MENA, India, Japan and Australia, representing ~A$1.4M+ in contracted revenue. Memphasys is focused on one objective: scaling Felix™ cartridge revenue across 5,000+ addressable IVF clinics worldwide.
Investor Highlights:
Record quarterly revenue: A$111.6k (March 2026) ~A$1.4M+ contracted multi-year revenue secured Commercially active in 7 markets (Europe, Australia, UK, MENA, India, Japan, New Zealand) CE Mark certified (December 2025) TGA registered (February 2026) UK MHRA registered Target cartridge price: $80–$150 per procedure 60%+ gross margin potential at target COGS 14+ granted patents (US and Australia) One cartridge per IVF cycle = $100k–$300k per clinic per year
For investor and media enquiries, please contact:
David Tasker, Managing Director,
Chapter One Advisors
Tel: +61 433 112 936
Email: dtasker@chapteroneadvisors.com.au